Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Cellectis Files IND For Talen-Edited 'Off-The-Shelf' CAR-T Candidate

Executive Summary

Cellectis has filed an IND for US testing of its TALEN-edited CAR-T immune-oncology therapy UCART123. Servier has already begun clinical testing with Cellectis' lead program, UCART19, in Europe. The product is licensed to Pfizer in the US.

You may also be interested in...



Pfizer Takes Step Back With Avelumab, Step Forward On CAR-T

Major changes to Phase III Lung 100 study of PD-L1 inhibitor avelumab mean a big delay for development in first-line lung cancer, but, separately, Pfizer advances in allogeneic CAR-T therapy with partners Servier and Cellectis.

Novartis, Kite Neck-And-Neck In CAR-T Race; Deaths Keep Juno In Third Place

Novartis and Kite both are set to submit their CD19-targeting CAR-T therapies for US FDA approval in early 2017, while neurotoxic deaths for two of Juno’s product candidates cast doubts on its programs.

CRISPR 'Not Good Enough' For CAR-T Product Manufacturing

CRISPR techniques are just not accurate enough for the precision gene editing required for the scalable manufacture of CAR-T therapies, according to Cellectis CEO Andre Choulika. Cellectis has an 'off the shelf' CAR-T product for the treatment of leukemia which targets the CD19 antigen, the same target other companies in the CAR-T space such as Novartis, Kite Pharma and Juno Therapeutics are focused on.

Related Content

Topics

Related Companies

UsernamePublicRestriction

Register

SC027449

Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel